Conference item
Early diagnosis of brain metastases through biofluid metabolomics
- Abstract:
- Over 20% of cancer patients develop brain metastases. Current MRI diagnostic techniques only detect late stage metastases, since they rely on blood-brain-barrier permeability to allow contrast enhancement. Thus, new methods enabling earlier diagnosis are urgently needed. We have previously shown that it is possible to discriminate between different inflammatory lesions in the CNS in rats (1), as well as between different stages of multiple sclerosis in patients (2), through biofluid (blood/urine) metabolomics. We believe that this ability is due, at least in part, to alterations in CNS metabolism, which provoke a specific metabolic signature in the biofluids studied. It is known that tumour metabolism differs markedly from normal brain and that brain metabolism itself will be altered by tumour presence. On the basis of the above, therefore, we hypothesised that the presence of brain metastases could be detected, in vivo, through NMR analysis of biofluids.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 208.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/neuonc/now292.010
Authors
- Publisher:
- Oxford University Press
- Host title:
- Neuro-Oncology
- Journal:
- British Neuro-Oncology Society Meeting 2016 (BNOS 2016) More from this journal
- Volume:
- 19
- Issue:
- suppl_1
- Pages:
- i26-i27
- Publication date:
- 2017-03-02
- Acceptance date:
- 2016-06-27
- DOI:
- ISSN:
-
1523-5866 and 1522-8517
- Pubs id:
-
pubs:719439
- UUID:
-
uuid:6926bdb1-bb90-4549-beef-d43af29f2c17
- Local pid:
-
pubs:719439
- Source identifiers:
-
719439
- Deposit date:
-
2018-10-30
Terms of use
- Copyright holder:
- Larkin et al
- Copyright date:
- 2017
- Notes:
- © The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]. This is the accepted manuscript version of the article. The final version is available online from Oxford University Press at: https://doi.org/10.1093/neuonc/now292.010 This abstract was presented at the 2016 British Neuro-Oncology Society Meeting (BNOS 2016)
If you are the owner of this record, you can report an update to it here: Report update to this record